Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors

Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis

(2021) Zoya Alteber et al.   Cancer Discovery

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function

(2019) Sarah Whelan et al.   Cancer Immunology Research

Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity

(2019) Benjamin Murter et al.   Cancer Immunology Research

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

(2019) Deepak Mittal et al.   Cancer Immunology Research

Targeting natural killer cells in solid tumors

(2019) Guillaume Habif et al.   Cellular & Molecular Immunology

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

(2019) Simona Sivori et al.   Cellular & Molecular Immunology

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy

(2019) Beatriz Sanchez-Correa et al.   Cancers

Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget

(2019) Xing Huang et al.   Cellular & Molecular Immunology

Targeting innate sensing in the tumor microenvironment to improve immunotherapy

(2019) Zhida Liu et al.   Cellular & Molecular Immunology

Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection

(2019) William H. Hudson et al.   IMMUNITY

Tumor intrinsic and extrinsic immune functions of CD155

(2019) Jake. S. O’Donnell et al.   SEMINARS IN CANCER BIOLOGY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade

(2018) Simone A. Minnie et al.   BLOOD

Targeting PVR (CD155) and its receptors in anti-tumor therapy

(2018) Paola Kučan Brlić et al.   Cellular & Molecular Immunology

Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma

(2018) Haoyu Sun et al.   HEPATOLOGY

Cancer immunologists scoop medicine Nobel prize

(2018) Heidi Ledford et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

(2017) Nicholas A. Manieri et al.   TRENDS IN IMMUNOLOGY

NK Cell Exhaustion

(2017) Jiacheng Bi et al.   Frontiers in Immunology

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

(2016) Y. Kong et al.   CLINICAL CANCER RESEARCH

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Identification of CD112R as a novel checkpoint for human T cells

(2016) Yuwen Zhu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

(2016) S. J. Blake et al.   Cancer Discovery

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit

(2014) Kristen E. Pauken et al.   CANCER CELL

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

(2014) Christopher J Chan et al.   NATURE IMMUNOLOGY

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers

(2013) Tsutomu Oshima et al.   Molecular Cancer

Establishment, Characterization, and Successful Adaptive Therapy against Human Tumors of NKG Cell, a New Human NK Cell Line

(2011) Min Cheng et al.   CELL TRANSPLANTATION

Accelerated tumor growth in mice deficient in DNAM-1 receptor

(2008) Akiko Iguchi-Manaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY